Hello. This is Paul Auwaerter with Medscape Infectious Diseases.
One presentation I want to mention briefly was about the rather remarkable effects of the pandemic on invasive group A streptococcus infections. Six years offrom the United Kingdom that covered the pandemic years showed that on average, there were 350 cases per year pre-pandemic, but in 2021, the number of cases fell to 29. The number of cases then rebounded in 2022 to 690.
Of course, it compared well, which isn't surprising. However, this is one of the first trials I've seen using the new composite endpoint from the FDA in uncomplicated UTI, a composite of both clinical and microbiological success. Both drugs scored far lower for the composite endpoint, at 50% and 47% for gepotidacin and nitrofurantoin, respectively, indicating that gepotidacin is noninferior, even though their clinical and microbiologic success rates independently were higher.